| pubmed-article:9416770 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C0032176 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C0292144 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C0055729 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:9416770 | lifeskim:mentions | umls-concept:C2348480 | lld:lifeskim |
| pubmed-article:9416770 | pubmed:issue | 25 | lld:pubmed |
| pubmed-article:9416770 | pubmed:dateCreated | 1998-1-14 | lld:pubmed |
| pubmed-article:9416770 | pubmed:abstractText | Cilostazol(6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4- dihydro-2(1H)-quinolinone) selectively inhibits cGMP-inhibited phosphodiesterase (PDE3) and is a potent inhibitor of platelet aggregation induced by various agonists. Effect of cilostazol on shear stress-induced human platelet aggregation (SIPA) was examined in vitro and ex vivo. Cilostazol inhibited SIPA dose-dependently in vitro. The IC50 value of cilostazol for inhibition of SIPA was 15 +/- 2.6 microM (m +/- SE, n=5), which was very similar to that (12.5 +/- 2.1 microM) for inhibition of ADP-induced platelet aggregation. Cilostazol potentiates the inhibition of SIPA by PGE1 and enhances its ability to increase cAMP concentrations. A single oral adminstration of 100 mg cilostazol to healthy volunteers produced a significant inhibition of SIPA. This study demonstrates that cilostazol is an effective inhibitor of SIPA, which may be important for the prevention and the treatment of arterial occlusive diseases. | lld:pubmed |
| pubmed-article:9416770 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9416770 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9416770 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9416770 | pubmed:issn | 0024-3205 | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:SuzukiYY | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:ShikuHH | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:IkedaYY | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:YamamotoMM | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:NishikawaMM | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:WadaHH | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:KimuraYY | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:MinamiNN | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:ImaiEE | lld:pubmed |
| pubmed-article:9416770 | pubmed:author | pubmed-author:KihiraHH | lld:pubmed |
| pubmed-article:9416770 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9416770 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:9416770 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9416770 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9416770 | pubmed:pagination | PL 383-9 | lld:pubmed |
| pubmed-article:9416770 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:meshHeading | pubmed-meshheading:9416770-... | lld:pubmed |
| pubmed-article:9416770 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9416770 | pubmed:articleTitle | Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. | lld:pubmed |
| pubmed-article:9416770 | pubmed:affiliation | The 2nd Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan. | lld:pubmed |
| pubmed-article:9416770 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9416770 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
